Minireviews
Copyright ©The Author(s) 2022.
World J Clin Oncol. Dec 24, 2022; 13(12): 943-956
Published online Dec 24, 2022. doi: 10.5306/wjco.v13.i12.943
Table 1 Short-term outcomes in randomized controlled trials of colonic stenting as a bridge to surgery
Ref.
Year
n
Perforation rate (%)
Stoma rate (%)
Morbidity (%)
Mortality (%)
Cheung et al[46]2009480SEMS, 0; ES, 25, (P = 0.03)aSEMS, 8; ES, 70; (P = N/A)N/A
Van Hooft et al[51]20119812SEMS, 57; ES, 66; (P = 0.35) SEMS, 53; ES, 45; (P = 0.43)SEMS, 19; ES, 17; (P = 0.84)
Pirlet et al[52] 2011606.6SEMS, 43; ES, 56; (P = 0.3)SEMS, 50; ES, 56; (P = 1)SEMS, 10; ES, 3; (P = N/A)
Alcántara et al[47]2011280N/ASEMS, 13; ES, 54; (P = 0.042)aSEMS, 0; ES, 8; (P = 0.46)
Ho et al[50]2012390SEMS, 10; ES, 31; (P = 0.12)SEMS, 35; ES, 58; (P = 0.15)SEMS, 0; ES, 16; (P = 0.1)
Ghazal et al[48]2013600N/ASEMS, 13; ES, 50; (P = 0.012)aSEMS, 0; ES, 0
Arezzo et al[15]20171158.9SEMS, 22; ES, 39; (P = 0.031)aSEMS, 52; ES, 58; (P = 0.529)SEMS, 7; ES, 5; (P = 0.943)
Elwan et al[49]2020 6010SEMS, 20; ES, 27; (P = N/A)SEMS, 23; ES, 40; (P = 0.029)aN/A
CReST trial[53]202221723.33SEMS, 43; ES, 67; (P < 0.001)aSEMS, 34; ES, 35; (P = 0.930)SEMS, 4; ES, 6; (P = 0.480)
Table 2 Long-term outcomes in randomized controlled trials of colonic stenting as a bridge to surgery
Ref.
Year
n
Perforation rate (%)
Median F/U time (mo)
Recurrence (%)
Overall survival (OS, %)
Disease-free survival (DFS, %)
Alcántara et al[47]201128038SEMS, 53; ES, 15; (P = 0.055)5-yr OS: SEMS, 60; ES, 68; (P = 0.843)Disease-free period (mo): SEMS, 25; ES, 27; (P = 0.096)
Tung et al[74]201348032SEMS, 46; ES, 13; (P = 0.400)5-yr OS: SEMS, 48; ES, 27; (P = 0.076)5-yr DFS: SEMS, 52; ES, 48; (P = 0.630)
Ghazal et al[48] 201360018SEMS, 17; ES, 13; (P = 0.228)N/AN/A
Sloothaak et al[57]2014582343SEMS, 50; ES, 28; (P = N/A)4-yr OS: SEMS, 58; ES, 67; (P = 0.478)4-yr DFS: SEMS, 30; ES, 49; (P=0.007)a
Arezzo et al[75]2020115      8.937SEMS, 28; ES, 36; (P = N/A)3-yr OS: SEMS, 63; ES, 68; (P = 0.822)3-yr DFS: SEMS, 50; ES, 56; (P = 0.972)
CReST trial[53]202221713.32N/A3-yr recurrence: SEMS, 43; ES, 34; (P = 0.340)3-yr OS: SEMS, 46; ES, 37; (P = 0.560)N/A